Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial

被引:11
|
作者
Winer, Rachel L. [1 ,2 ]
Lin, John [1 ]
Anderson, Melissa L. [2 ]
Tiro, Jasmin A. [3 ]
Green, Beverly B. [2 ,4 ]
Gao, Hongyuan [2 ]
Meenan, Richard T. [5 ]
Hansen, Kristina [2 ]
Sparks, Angela [6 ,7 ,8 ]
Buist, Diana S. M. [1 ,9 ]
机构
[1] Univ Washington, Dept Epidemiol, 3980 15th Ave NE,Box 351619, Seattle, WA 98195 USA
[2] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA
[3] Univ Chicago, Biol Sci Div, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[4] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA USA
[5] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA
[6] Washington Permanente Med Grp, Seattle, WA USA
[7] Washington Permanente Med Grp, Seatac, WA USA
[8] UnitedHealthcare Community Plan Washington, Seatac, WA USA
[9] GRAIL LLC, Menlo Pk, CA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2023年 / 330卷 / 20期
基金
美国国家卫生研究院;
关键词
WOMEN; BARRIERS;
D O I
10.1001/jama.2023.21471
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Optimal strategies for increasing cervical cancer screening may differ by patient screening history and health care setting. Mailing human papillomavirus (HPV) self-sampling kits to individuals who are overdue for screening increases adherence; however, offering self-sampling kits to screening-adherent individuals has not been evaluated in the US. OBJECTIVE To evaluate the effectiveness of direct-mail and opt-in approaches for offering HPV self-sampling kits to individuals by cervical cancer screening history (screening-adherent and currently due, overdue, or unknown). DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial conducted in Kaiser Permanente Washington, a US integrated health care delivery system. Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled between November 20, 2020, and January 28, 2022, with follow-up through July 29, 2022. INTERVENTIONS Individuals stratified as due (eg, at the time of randomization, these individuals have been previously screened and are due for their next screening in <= 3 months) were randomized to receive usual care (patient reminders and clinician EHR alerts [n=3671]), education (usual care plus educational materials about screening [n=3960]), direct mail (usual care plus educational materials and a mailed self-sampling kit [n=1482]), or to opt in (usual care plus educational materials and the option to request a kit [n=3956]). Individuals who were overdue for screening were randomized to receive usual care (n=5488), education (n=1408), or direct mail (n=1415). Individuals with unknown history for screening were randomized to receive usual care (n=2983), education (n=3486), or to opt in (n=3506). MAIN OUTCOMES AND MEASURES The primary outcome was screening completion within 6 months. Primary analyses compared direct-mail or opt-in participants with individuals randomized to the education group. RESULTS The intention-to-treat analyses included 31355 randomized individuals (mean [SD] age, 45.9 [10.4] years). Among those who were due for screening, compared with receiving education alone (1885 [47.6%]), screening completion was 14.1% (95% CI, 11.2%-16.9%) higher in the direct-mail group (914 [61.7%]) and 3.5% (95% CI, 1.2%-5.7%) higher in the opt-in group (2020 [51.1%]). Among individuals who were overdue, screening completion was 16.9% (95% CI, 13.8%-20.0%) higher in the direct-mail group (505 [35.7%]) compared with education alone (264 [18.8%]). Among those with unknown history, screening was 2.2% (95% CI, 0.5%-3.9%) higher in the opt-in group (634 [18.1%]) compared with education alone (555 [15.9%]). CONCLUSIONS AND RELEVANCE Within a US health care system, direct-mail self-sampling increased cervical cancer screening by more than 14% in individuals who were due or overdue for cervical cancer screening. The opt-in approach minimally increased screening. To increase screening adherence, systems implementing HPV self-sampling should prioritize direct-mail outreach for individuals who are due or overdue for screening. For individuals with unknown screening history, testing alternative outreach approaches and additional efforts to document screening history are warranted.
引用
收藏
页码:1971 / 1981
页数:11
相关论文
共 50 条
  • [31] Can Human Papillomavirus DNA Self-sampling be an Acceptable and Reliable Option for Cervical Cancer Screening in Female Sex Workers?
    Wong, Eliza L. Y.
    Cheung, Annie W. L.
    Huang, Fenwei
    Chor, Josette S. Y.
    CANCER NURSING, 2018, 41 (01) : 45 - 52
  • [32] Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial
    Haguenoer, K.
    Sengchanh, S.
    Gaudy-Graffin, C.
    Boyard, J.
    Fontenay, R.
    Marret, H.
    Goudeau, A.
    de Laroche, N. Pigneaux
    Rusch, E.
    Giraudeau, B.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2187 - 2196
  • [33] Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial
    Viviano, Manuela
    Catarino, Rosa
    Jeannot, Emilien
    Boulvain, Michel
    Malinverno, Manuela Undurraga
    Vassilakos, Pierre
    Petignat, Patrick
    BRITISH JOURNAL OF CANCER, 2017, 116 (11) : 1382 - 1388
  • [34] Human papillomavirus self-sampling with mRNA testing benefits routine screening
    Auvinen, Eeva
    Nieminen, Pekka
    Pellinen, Jukka
    Dillner, Joakim
    Tarkkanen, Jussi
    Virtanen, Anni
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (11) : 1989 - 1996
  • [35] Worldwide use of HPV self-sampling for cervical cancer screening
    Serrano, B.
    Ibanez, R.
    Robles, C.
    Peremiquel-Trillas, P.
    de Sanjose, S.
    Bruni, L.
    PREVENTIVE MEDICINE, 2022, 154
  • [36] Self-Sampling for Human Papillomavirus Testing among Non-Attenders Increases Attendance to the Norwegian Cervical Cancer Screening Programme
    Enerly, Espen
    Bonde, Jesper
    Schee, Kristina
    Pedersen, Helle
    Lonnberg, Stefan
    Nygard, Mari
    PLOS ONE, 2016, 11 (04):
  • [37] Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a US healthcare system
    Winer, Rachel L.
    Tiro, Jasmin A.
    Miglioretti, Diana L.
    Thayer, Chris
    Beatty, Tara
    Lin, John
    Gao, Hongyuan
    Kimbel, Kilian
    Buist, Diana S. M.
    CONTEMPORARY CLINICAL TRIALS, 2018, 64 : 77 - 87
  • [38] A Home-Mailed Versus General Practitioner-Delivered Vaginal Self-Sampling Kit for Cervical Cancer Screening: A Cluster Randomized Controlled Trial with a Cost-Effectiveness Analysis
    Boyard, Julie
    Caille, Agnes
    Brunet-Houdard, Solene
    Sengchanh-Vidal, Somany
    Giraudeau, Bruno
    Marret, Henri
    Rolland-Lozachmeur, Ghislaine
    Rusch, Emmanuel
    Gaudy-Graffin, Catherine
    Haguenoer, Ken
    JOURNAL OF WOMENS HEALTH, 2022, 31 (10) : 1472 - 1480
  • [39] "It's cancer screening after all". Barriers to cervical and colorectal cancer screening and attitudes to promotion of self-sampling kits upon attendance for breast cancer screening
    Kirkegaard, Pia
    Larsen, Mette Bach
    Andersen, Berit
    JOURNAL OF MEDICAL SCREENING, 2023, 30 (02) : 74 - 80
  • [40] Promotion of Cervical Screening among Long-term Non-attendees by Human Papillomavirus Self-sampling
    Ernstson, Avalon
    Forslund, Ola
    Borgfeldt, Christer
    JOURNAL OF CANCER PREVENTION, 2021, 26 (01) : 25 - 31